This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ITGA7 · Western blot design guide
ITGA7 Western Blot Planning Guide
Plan an ITGA7 Western blot around the catalog-observed 128.9 kDa band, image-backed PA2226 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
ITGA7 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 128.9 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Adipose tissue | |
| Negative control | Endometrium |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 128.9 kDa |
| ⓘ | Localization | Membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Rat / Mouse / Human |
Sample controls for ITGA7 Western blot
🧪Use Adipose tissue as the first positive-control candidate and Endometrium as the HPA Not detected negative candidate.
Positive control: Adipose tissue (Medium)
Negative control: Endometrium (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for ITGA7
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart on each tissue page — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Bone marrow | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Bronchus | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 1
What Is the Expected ITGA7 Western Blot Band Size?
Use the product-observed 128.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 128.9 kDa | Matches the authoritative product WB observation. |
| 128.9 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected ITGA7 appearancePlan around 128.9 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 128.9 kDa; use this as the primary experimental expectation. |
| Calculated mass | 128.9 kDa from UniProt Q13683; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PA2226. |
| Situation | Likely cause | Next action |
|---|---|---|
| 128.9 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing ITGA7 band
PA2226 · ITGA7Observed 128.9 kDa · product-specific WB image
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Section 2
Real Curated ITGA7 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adipose tissue |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PA2226 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 4
Advanced ITGA7 Western Blot Tips
Deeper troubleshooting and optimisation questions for ITGA7, answered from its protein features.
Which band should guide the blot?
Use 128.9 kDa, the observation attached to the authoritative PA2226 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 128.9 kDa expectation.
Which positive control should I start with?
Start with Adipose tissue, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Endometrium as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for ITGA7 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PA2226 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC8657770, PMC9143933, PMC9713827.
Boster reagents
ITGA7 Western Blot Reagents
Rat/Mouse/Human-reactive ITGA7 Western blot reagents with authoritative product imagery.
Real WB data
Anti-Integrin alpha-7 ITGA7 Antibody Picoband®
Cat # PA2226
Reactivity: Rat, Mouse, Human
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q13683
- Human Protein Atlas — ITGA7
- PA2226 product record
- PMC8657770 — Decrease in ITGA7 Levels Is Associated with an Increase in α-Synuclein Levels in an MPTP-Induced Parkinson's Disease Mouse Model and SH-SY5Y Cells.
- PMC9143933 — Association between Decreased ITGA7 Levels and Increased Muscle α-Synuclein in an MPTP-Induced Mouse Model of Parkinson's Disease.
- PMC9713827 — Effect of integrin α7 on cell proliferation, invasion, apoptosis and the PI3K/AKT pathway, and its association with clinicopathological features in endometrial cancer.